CBR96-doxorubicin immunoconjugate

From Wikipedia, the free encyclopedia
Jump to: navigation, search
CBR96-doxorubicin immunoconjugate ?
Monoclonal antibody
Source Humanized (from mouse)
Target Lewis-Y antigen
Clinical data
Legal status
?
Identifiers
ATC code None
Synonyms SGN-15, BMS-182248
Chemical data
Formula ?

cBR96-doxorubicin immunoconjugate (BMS-182248/SGN-15) was an antibody-drug conjugate (ADC) directed to the Lewis-Y antigen designed for the treatment of cancer. The payload was doxorubicin which was connected with a hydrazone linker to cysteine residues of the Lewis-Y specific monoclonal antibody BR96.[1] Clinical development of cBR96-doxorubicin immunoconjugate was discontinued.

References[edit]

  1. ^ http://adcreview.com/page/harnessing-the-power-of-three-advancing-antibody-drug-conjugates-